CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

First patient dosed in MacroGenics’ Phase I MGC030 trial

Trial StartMGC030Neutral
AI Analysis

Summary

MacroGenics has dosed the first patient in a Phase I study of its investigational therapy MGC030 for advanced solid tumours.

Clinical Trial Data

Phase

Phase_1

Outcome Details

First patient dosed in Phase I study of MGC030

Importance:4/10
Sentiment:
0.20
Phase 1first patient dosedoncologysolid tumorsMacroGenicsMGC030
Related Companies
$MGNX

Read the original article

Published by Clinical Trials Arena on October 16, 2026 10:10 AM

Read Original